Abstract. Autophagy has been recognized as an important element of tumor cell migration, invasion, and chemo resistance, and our previous results showed that Beclin-1-mediated autophagy contributed to osteosarcoma chemoresistance. However, the regulating mechanism of autophagy is still unclear. In this study, our aim was to clarify microRNA (miRNA)-related mechanisms underlying Beclin-1-mediated autophagy followed by chemotherapy in osteosarcoma. First, miRNA screening using qRT-PCR identified that miR-30a was significantly reduced in Dox-resistant osteosarcoma cells. Second, the autophagy activity in Dox-resistant increased while miR-30a expression reduced after chemotherapy agents as indicated by the enhanced expression of Beclin-1, the increased conversion of microtubule-associated protein LC3-I to LC3-II. Furthermore, overexpression of miR-30a significantly promoted chemotherapy-induced apoptosis and reduced autophagy activity responding to chemotherapy. Moreover, rapamycin, an autophagy promoter was able to partly reverse the effect of miR-30a and Luciferase reporter assay identified that miR-30a directly binds to the 3'-UTR of Beclin-1 gene, which further confirmed that miR-30a reduced chemoresistance via suppressing Beclin-1-mediated autophagy. Collectively these results indicate miR-30a and its downstream target gene Beclin-1 can be used in treatment of osteosarcoma chemo resistance in the future.
Introduction
Osteosarcoma is one of the most common malignant bone tumor in childhood (1) , but it is difficult to cure, especially during the later stages. Chemoresistance is a main cause of unsatisfactory survival outcomes, although chemotherapy has become more effective in recent years (2, 3) . Several factors are implicated in the development of chemoresistance including genetic alterations, drug uptake and increased activation of DNA repair mechanisms and evasion of chemotherapyinduced apoptosis (4, 5) . Additionally, our previous results showed that Beclin-1-mediated autophagy contributed to osteosarcoma chemoresistance (6) . However, the molecular regulating mechanism of autophagy in chemoresistance is largely unclear.
MicroRNA (miRNA), an endogenous noncoding RNA with 18-25 nucleotides, is able to regulate gene expression by binding to the 3'-untranslated region (3'-UTR) of their target mRNAs, modulating mRNA and protein expression. A series studies on miRNAs in osteosarcoma have been performed and several miRNAs contribute to the development and progression of osteosarcoma (2, (7) (8) (9) . miR-30a, an intronic transcriptional unit, was widely expressed in various tissues (10) . Recent studies have suggested that miR-30a played a tumorsuppressive role in various malignant tumors, including lung cancer (11) , breast cancer (12) , colon cancer (13) , and nasopharyngeal carcinoma (14) . Moreover, a negative correlation was observed between miR-30a expression and malignant grade in osteosarcoma. Importantly, overexpression of miR-30a reduced proliferation, migration, and invasion and further studies revealed that runt-related transcription factor 2 was a regulative target gene of miR-30a (7) . However, the role of miR-30a in osteosarcoma chemoresistance remains elusive.
Autophagy is essential for the maintenance of cellular biosynthesis, growth and differentiation. Accumulating evidence supports that activation of autophagy was also a crucial step in the process of chemoresistance (15) . Since autophagy promoted tumor cells to survive under adverse stress conditions, such as hypoxia, ischemia and chemotherapy (16) . Recent studies indicated microRNA-143 (17), miR-101 (18), and miR-22 (19) to be involved in chemoresistance through regulating autophagy. Therefore, a better understanding of the role of miRNA-mediated autophagy in osteosarcoma is essential for future treatment in chemoresistance.
In this study, we investigated the expression of miR-30a in osteosarcoma cell lines. We demonstrated autophagy was activated by chemotherapy and miR-30a was downregulated following chemotherapy. Further study showed that over expression of miR-30a reduced chemoresistance of osteosarcoma cells through downregulating autophagy. In addition, Beclin-1 was identified as the target gene of miR-30a in osteosarcoma. The above results indicate miR-30a and its downstream target gene Beclin-1 can be used in treatment of osteosarcoma chemo resistance in the future.
Materials and methods

Cell culture and doxorubicin-resistant MG-63 cell line.
Human osteosarcoma MG-63 cell line was preserved in our laboratory as previously described (20) . Cells was cultured in high glucose DMeM medium supplemented with 10% fetal bovine serum (gibco, Carlsbad, CA, USA), 100 U/ml penicillin, and 100 µg/ml streptomycin, and were cultured in a humidified atmosphere containing 5% Co 2 at 37˚C. A doxorubicin (Dox)-resistant cell line (Mg-63/Dox) was established from its parental cell line MG-63 by gradually increasing the concentration of Dox over 6 months. The concentration of Dox added to Mg-63 cells was from 10 to 100 nM, after which the cells were maintained in culture medium containing 100 nM Dox, it displayed 6-fold resistance to Dox compared with the corresponding parental sensitive cells.
Quantitative real-time RT-PCR. Total RNA containing miRNA was extracted from cells with TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. miR-30a and U6 small nuclear 2 (U6) expression was detected from the cDNA product using TaqMan miRNA sequence-specific probes (Takara, Japan) and ABI Prism 7500 sequence detection system (Applied Biosystems, Foster City, CA, USA ) were seeded in 96-well plates and cultured for 1, 2, 3, 4 and 5 days after transfection. CCK-8 solution (10 µl) was added to each well and followed by incubation for 2 h. Absorbance was measured at 450 nm with a Microplate Autoreader (Bio-Rad, Hercules, CA, USA). For apoptosis detection, miR-30a transfected cells in the presence or absence of chemotherapy agents were stained with Annexin V/PI double staining kit (BD Biosciences, Bedford, MA, USA) according to the manufacturer's protocol. Apoptotic cells were examined by flow cyto metry (6) .
Western blot analysis. Proteins were separated by 10% SDS pages and then performed as previously described (6) . Antibodies against Beclin-1, p62, LC3-I, LC3-II, cleaved caspase-3, Total caspase-3, and β-actin were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Then the band were incubated by horseradish peroxidase-labeled goat anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and detected by chemiluminescence. β-actin was used as a protein loading control.
Stably expressing GFP-LC3. The adenovirus vector containing the GFP-LC3 reporter was purchased from Hanbio (Shanghai, China). In the presence or absence of chemotherapy, the cells were analyzed by a fluorescence microscope (olympus, Tokyo, Japan).
Luciferase reporter assay. According to the expression of miR-30a with the Beclin-1 3'-UTR, 3'-UTR sequence or three copies of the mutated 3'-UTR sequence of Beclin-1 were amplified by PCR from human genomic DNA and immediately inserted into pGL3-control vector (Promega Corp., WI, USA). Mg-63/Dox cells in 6-well plates were transfected with 1 µg of the firefly luciferase report vector, 1 h post-transfection with 25 nM of mimic NC, miR-30a mimics, anti-NC or anti-miR-30a. At 24 h post-transfection, firefly luciferase activities were measured consecutively using luciferase assays (Promega Corp.).
Statistical analysis.
The data are expressed as means ± standard error (Se). A two-tailed Student's t-test was used to determine the significance of differences between groups. Results with P-values <0.05 were considered statistically significant and SPSS 13.0 was used for the statistical analysis.
Results
Autophagy is increased in Dox-resistant osteosarcoma cells and miR-30a is downregulated.
Dox has been widely used in clinical chemotherapy of osteosarcoma patients, we established the Dox-resistant Mg-63 cells. In terms of IC 50 , the Dox-selected Mg-63/Dox subline showed 6-fold higher resistance to doxorubicin (Dox), 2.2-fold, and 2-fold higher resistance to cisplatin (Cis), and methotrexate (Mtx), respectively, when compared with parental MG-63cells. The results indicated that Mg-63/Dox subline was cross-resistant to the conventional chemotherapeutic agents (Fig. 1A) .
Next, we assessed the autophagy activity of the above two different osteosarcoma cells, by using LC3-GFPlabeled autophagosomes, which indicated that the level of autophagy was significantly increased in Mg-63/Dox subline cells (Fig. 1B) . Western blot analysis confirmed that the autophagy-related protein Beclin-1 increased in Mg-63/Dox cells compared with the control cells (Fig. 1C) . The autophagy-related protein LC3-I and LC3-II was also higher in the Mg-63/Dox cells as compared with the control cells (Fig. 1C) .
Using a TaqMan probe-based qRT-PCR assay, we determined the expression levels of a panel of miRNAs that have been reported to be associated with osteosarcoma cellular autophagy and chemoresistance, particularly miR-1, miR-30a, miR-133a, miR-133b, miR-208b and miR-378c (21) . As shown in Fig. 1D , among the 6 miRNAs tested, a largest reduction of miR-30a was observed in Mg-63/Dox cells compared with the control cells.
miR-30a overexpression suppresses Beclin-1 expression and autophagy is induced by chemotherapy. Subsequently, we assayed the effects of the anticancer agents on the expression of miR-30a. As shown in Fig. 2A and B, anticancer agents significantly suppressed the expression of miR-30a in both Mg-63 and Mg-63/Dox cell lines. These findings show that miR-30a expression was downregulated during chemotherapy in osteosarcoma cells.
To further investigate the possible role of miR-30a in the Mg-63/Dox osteosarcoma cells, we applied lentivirus system to make stable cell lines to overexpress miR-30a on the base of osteosarcoma cell line Mg-63/Dox including a blank group (untransfected cells), a Lenti-NC group (cells transfected with the control lentivirus), and a Lenti-miR-30a group (overexpressing of miR-30a). The miR-30a expression levels in these groups were evaluated using qRT-PCR. As expected, the expression of miR-30a was increased in Lenti-miR-30a group cells (P<0.05) (Fig. 2C) . Next, we investigated the effect of miR-30a on autophagy. Results showed that miR-30a overexpression significantly decreased Beclin-1, LC3-I and LC3-II expression, while miR-30a increased p62 protein level (Fig. 2D) . A significantly decreased accumulation of LC3-GFP punctae were also confirmed by confocal assay in Mg-63/miR-30a cells. These results revealed that overexpressed miR-30a inhibited autophagy in Mg-63/Dox cells (Fig. 2e) .
To further explore the function of miR-30a in the chemoresistance of osteosarcoma, cell proliferation assays were performed to determine cell growth curve and 50% inhibition of growth (IC 50 ) values following chemotherapy treatment. overexpression of miR-140-5p did not alter cell growth (Fig. 2F) . Remarkably, overexpression of miR-30a dramatically reduced the IC 50 values for the three chemotherapeutic agents in MG-63 cells (Fig. 2G) .
miR-30a promotes chemotherapy-induced osteosarcoma cell apoptosis via repressing Beclin-1-mediated osteosarcoma autophagy. As shown in Fig. 3A and B, after chemotherapy treatments for 12 h, the ratio of LC3-II versus LC3-I was increased from 2.2-3.5 in the lenti-NC cells in relative to 1.3-1.5 range in lenti-miR-30a group (Fig. 1A) . Consistently, the level of Beclin-1 proteins was greatly increased about 1.5-, 1.8-and 2.7-fold in lenti-NC group as compared with 1.1-, 1.23-and 1.28-fold in lenti-miR-30a group, respectively. The above data suggested that miR-30a overexpression led to a down regulation of autophagy responding to chemotherapy in Mg-63/Dox osteosarcoma cells. Importantly, apoptosis in Mg-63/miR-30a cells was assessed after chemotherapy. Chemotherapy treatment for 12 h showed 2.6-fold, 1.8-fold, 1.9-fold increase in apoptosis incidence in the Lenti-miR-30a group as compared with the counterparts, respectively. Furthermore, to determine the role of downregulated autophagy in Mg-63/miR-30a cells, autophagy was activated by rapamycin, an autophagy promoter. As a result, rapamycin could partly decrease the Dox-induced apoptosis, suggesting that activating autophagy reversed the effect of miR-30a. Additionally, the apoptotic markers were assessed by western blotting. Compared with the lenti-NC group, the level of cleaved caspase-3 was increased in Lenti-miR-30a group following Dox treatment, suggesting that miR-30a promoted Dox-induced apoptosis. Consistently, rapamycin could partly reduce the expression of cleaved caspase-3. These results showed that miR-30a overexpression could promote Dox-induced apoptosis of osteosarcoma cells through suppressing autophagy.
Beclin-1 is a target of miR-30a in osteosarcoma.
It has been reported that Beclin-1 is the direct target of miR-30a in the breast cancer cell line MCF-7 (22), and we reasoned that miR-30a may have a similar regulating effect on osteosarcoma. Binding sites for miR-30a in the 3'-UTR of Beclin-1 were identified by bioinformatics analysis (Fig. 4A) .
To further assess whether miR-30a was directly targeting Beclin-1 expression through the target site in the 3'-UTR of Beclin-1, reporter constructs containing either the wild-type (WT) Beclin-1 3'-UTR or Beclin-1 3'-UTR with mutation at the predicted miR-30a target sequence were cotransfected into MG-63 cells together with mimic NC, miR-30a mimics, anti-NC or anti-miR-30a. Luciferase reporter assays showed that transduction of miR-30a mimics substantially inhibited the luciferase activity of the wild-type Beclin-1 3'-UTR by ~42% in Mg-63 cells, but had no effect on mutant Mg-63 3'-UTR relative to the control (Fig. 4B) , and cotransfection with anti-miR-30a significantly increased luciferase activity of WT Beclin-1 3'UTR-compared with anti-NC control (Fig. 4B) . Whereas, transfection of the mutant Beclin-1 3'-UTR with anti-miR-30a had no effect on luciferase activity. The above results strongly suggested that Beclin-1 was a direct target of miR-30a in osteosarcoma cells.
To further examine whether miR-30a modulated the expression of Beclin-1 in osteosarcoma, cells were transfected with mimic NC, miR-30a mimics, anti-NC or anti-miR-30a and then the mRNA expressions of miR-30a and Beclin-1 were analyzed by real-time PCR. Transfection of the miR-30a mimics significantly increased the miR-30a expression and decreased the mRNA level of Beclin-1. Consistently, antimiR-30a had the opposite effects on expression in miR-30a and Beclin-1 ( Fig. 4C and D) .
Discussion
With the advancement of neoadjuvent chemotherapy, the global survival rate of osteosarcoma improved to ~70% (23).
however, like most malignant cancers, ~30% of patients will develop relapse and chemoresistance, which is the major reason for recurrence of osteosarcoma (24) . Previously, we investigated the role of Beclin-1 in osteosarcoma, and suggested that the knockdown of Beclin-1 rendered osteosarcoma cells more sensitive to chemotherapy (6) . In this study, we observed that chemotherapy induced downregulation of miR-30a in osteosarcoma cells, suggesting that miR-30a might participate in osteosarcoma chemoresistance. Consistently, downregulation of miR-30a has been reported in diverse cancers, and to be involved in tumor cell proliferation and metastasis (11) (12) (13) (14) . However, little is known about contribution of miR-30a to chemoresistance of osteosarcoma. Thus, we further investigated the expression of miR-30a in Dox-resistant osteosarcoma. our results showed there was a significant downregulation of miR-30a and increased autophagy in Dox-resistant osteosarcoma cell line MG-63, which suggested that miR-30a might be a suppressor for autophagy. Next, to further confirm the biological role of miR-30a in osteosarcoma, miR-30a was overexpressed in Dox-resistance osteosarcoma cell line Mg-63/Dox. Real-time PCR confirmed that miR-30a was lowly expressed in Mg-63/Dox cells. overexpression of miR-30a did not alter osteosarcoma cell growth, but it significantly suppressed the autophagy activity of osteosarcoma cells, indicating that miR-30a should be a suppressor for autophagy. Given that autophagy is implicated in chemoresistance (25) (26) (27) , it was likely that miR-30a downregulation contributed to chemoresistance of osteosarcoma cells by suppressing autophagy, which might explain the parallel downregulation of miR-30a and elevated autophagy in Dox-resistance Mg-63 cells.
Autophagy is an essential pathway for cellular homeostasis and recent studies demonstrated that autophagy is implicated in chemoresistance (25) (26) (27) . However, the regulating mechanism of autophagy in osteosarcoma is still unclear. Our data showed downregulation of miR-30a in Dox-resistance osteosarcoma, consistent with the result in mouse human macrophages (28) . Then, it was necessary to clarify whether miR-30a affects the chemoresistance of osteosarcoma. Thus, we next examined the effects of miR-3a on osteosarcoma cell death in the presence of chemotherapy. The data showed that miR-30a strongly reduced the IC 50 values and significantly promoted chemotherapy-induced cell death, suggesting that overexpression of miR-30a rendered osteosarcoma cells more sensitive to chemotherapy.
Notably, western blot analysis demonstrated that overexpression of miR-30a enhanced doxorubicin-induced caspase-3 cleavage, whereas autophagy promoter, rapamycin attenuated doxorubicin-induced caspase-3 cleavage and reversed the effect of miR-30a. These results strongly suggested that over expression of miR-30a decreased chemoresistance by suppressing autophagy, leading to increased doxorubicininduced cell death. Several studies have demonstrated that inhibiting autophagy sensitizes tumor cells to chemotherapyinduced cell death, suggesting a key role for the miR-30a/ autophagy loop in chemoresistance of osteosarcoma (25, 29) . Therefore, it was reasonable that downregulation of miR-30a contributed to chemoresistance of osteosarcoma cells through regulating autophagy. Furthermore, to investigate the mechanism of miR-130a in regulating autophagy, bioinformatics analysis was performed. The results showed that the 3'-UTR region of Beclin-1 were the binding sites for miR-30a. Consistently, previous studies demonstrated that Beclin-1 was the directly target of miR-30a (30) . The study of the miR-30a/autophagy loop is based on our previous results and this is the first study of miR-30a in the chemoresistance of osteosarcoma. Our work led to the identification of a novel functional pathway controlled by miR-30a and its direct target, Beclin-1, that regulated chemoresistance in osteosarcoma. Therefore, miR-30a and its target gene pathway may represent new therapeutic opportunities for chemoresistant patients.
